Verastem, Inc.
http://www.verastem.com
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Verastem, Inc.
Verastem RAMPS Up In Rare Ovarian Cancer With Avutometinib/Defactinib Filing
The company announced topline data from the RAMP 201 trial in low-grade serous ovarian cancer, a rare disease with no FDA-approved treatments, and started a rolling FDA submission.
Deal Watch: Novo Nordisk Builds On Metabolic Strength Acquiring Partner Embark
Bristol and Regeneron sign separate cell therapy technology pacts, plus deals involving Takeda/ImmunoGen, Serina/AgeX, Cybin/Small Pharma, Taiho/Phost’in, Royalty/Ferring and Aardvark/GRI Bio.
Finance Watch: Signs Of Life? A Small Offering, Three New Filings And Galderma Hints At An IPO
Public Company Edition: Private Galderma raised $1bn but said its next likely financing will be an IPO. Also, Azitra went public while Turnstone, Apogee and Sagimet initiated the process; Sutro signed a royalty deal for up to $390m; and despite a follow-on offering mini-surge, cost cuts continue.
Yakult's Japan Duvelisib Decision Casts New Shadow Over Shrinking Pharma Ops
Yakult’s decision to pull an approval application for duvelisib in Japan came shortly after a FDA advisory committee said it would re-evaluate the safety and efficacy of the PI3K inhibitor four years since its approval. The developments cast a new shadow over Yakult’s already-suffering pharmaceutical business.
Company Information
- Industry
- Biotechnology
- Pharmaceuticals
-
In Vitro Diagnostics
- Molecular Diagnostics & Genetic Testing
-
Biotechnology
- Pharmacogenetics-Pharmacogenomics
- Other Names / Subsidiaries
-
- Verastem Oncology
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice